Assessment of the radioprotective effects of amifostine and melatonin on human lymphocytes irradiated with gamma-rays In vitro

Arhiv za Higijenu Rada i Toksikologiju

Volumn 57, Issue 2, 2006, Pages 155-163

  Kopjar, Nevenka ^a   Miočić, Slavica ^b   Ramić, Snježana ^a   Milić, Mirta ^a   Viculin, Tomislav ^c  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Ionising radiation; Peripheral blood; Radioprotectors

Indexed keywords

AMIFOSTINE; COBALT 60; MELATONIN; RADIOPROTECTIVE AGENT;

CHROMOSOME DAMAGE; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; GAMMA RADIATION; GENOTOXICITY; HUMAN; IN VITRO STUDY; IONIZING RADIATION; IRRADIATION; LYMPHOCYTE PROLIFERATION; MALE; MICRONUCLEUS TEST; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; RADIATION DOSE; RADIATION PROTECTION; RADIATION RESPONSE; SISTER CHROMATID EXCHANGE; UNSPECIFIED SIDE EFFECT;

ADULT; AMIFOSTINE; CELL CYCLE; DNA DAMAGE; GAMMA RAYS; HUMANS; LYMPHOCYTES; MALE; MELATONIN; MICRONUCLEUS TESTS; RADIATION-PROTECTIVE AGENTS; SISTER CHROMATID EXCHANGE;

EID: 33745589798     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Bartelink H, Schellens JHM, Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 2002;38:216-22.
2. Harrison L, Malyarchuk S. Can DNA repair cause enhanced cell killing following treatment with ionising radiation? Pathophysiology 2002;8:149-59.
3. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18(19):3339-45.
4. Brenner B, Wasserman L, Beery E, Nordenberg J, Schechter J, Gutman H, Fenig E. Variable cytotoxicity of amifostine in malignant and non-malignant cell lines. Oncol Rep 2003;10:1609-13.
5. Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionising radiation. Proc Soc Exp Biol Med 2000;225:9-22.
6. Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR. Melatonin as a radioprotective agent: a review. Int J Radiation Oncology Biol Phys 2004;59:639-53.
7. Vijayalaxmi, Reiter RJ, Meltz ML, Herman TS. Melatonin: possible mechanisms involved in its 'radioprotective' effect. Mutat Res 1998;404:187-9.
8. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ, Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG. American Society of Clinical Oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
9. Snyder RD, Grdina DJ. Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase II. Cancer Res 2000;60:1186-8.
10. De Souza CA, Santini G, Marino G, Nati S, Congiu AM, Vigorito AC, Damasio E. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study. Braz J Med Biol Res 2000;33:791-8.
11. Kouloulias VE, Kouvaris JR, Kokakis JD, Kostakopoulos A, Mallas E, Metafa A, Vlahos LJ. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis. Int J Radiat Oncol 2004;59:1148-56.
12. McCumber LM. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine. Med Dosim 2004;29:139-43.
13. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000;57:113-8.
14. Badr FM, El Habit OHM, Harraz MM. Radioprotective effect of melatonin assessed by measuring chromosomal damage in mitotic and meiotic cells. Mutat Res 1999;444:367-72.
15. International Atomic Energy Agency (IAEA). Cytogenetic Analysis for Radiation Dose Assessment. Technical Reports Series No. 405. Vienna: IAEA; 2001.
16. Fenech M, Morley AA. Measurement of micronuclei in lymphocytes. Mutat Res 1985;147:29-36.
17. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 2003;534:65-75.
18. Eastmond DA, Tucker JD. Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and antikinetochore antibody. Environ Mol Mutagen 1989;13:34-43.
19. Latt S, Allen J, Bloom SE, Carrano A, Falke E, Kram D, Schneider E, Schreck R, Tice R, Whitfield B, Wolff S. Sister chromatid exchanges: a report of the Gene-Tox Program. Mutat Res 1981;87:17-62.
20. Lamberti LP, Bigatti Ponzetto P, Ardito G. Cell kinetics and sister-chromatid exchange frequency in human lymphocytes. Mutat Res 1983;120:193-9.
21. Vijayalaxmi, Meltz ML, Reiter RJ, Herman TS, Kumar KS. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat Res 1999;425:21-7.
22. Gantenberg HW, Wuttke K, Streffer C, Müller WE. Micronuclei in human lymphocytes irradiated in vitro and in vivo. Radiat Res 1991;128:276-81.
23. Müller WE, Nüsse M, Miller BM, Slavotinek A, Viaggi S, Streffer C. Micronuclei: a biological indicator of radiation damage. Mutat Res 1996;366:163-9.
24. Chang WP, Hsieh WA, Chen DP, Lin YP, Hwang JS, Hwang JJJ, Tsai MH, Hwang BF. Change in centromeric and acentromeric micronucleus frequencies in human populations after chronic radiation exposure. Mutagenesis 1999;14:427-32.
25. Lee TK, O'Brien K, Eaves GS, Christie KI, Varga L. Effect of blood storage on radiation-induced micronuclei in human lymphocytes. Mutat Res 1999;444:201-6.
26. Palyvoda O, Polańska J, Wygoda A, Rzeszowska-Wolny J. DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta Biochim Pol 2003;50:181-90.
27. Gutiérrez S, Carbonell E, Galofré P, Creus A, Marcos R. Low sensitivity of the sister chromatid exchange assay to detect the genotoxic effects of radioiodine therapy. Mutagenesis 1999;14:221-6.
28. Iijima K, Morimoto K. Quantitative analyses of the induction of chromosome aberrations and sister-chromatid exchanges in human lymphocytes exposed to γ-rays and mitomicin-C in combination. Mutat Res 1991;263:263-8.
29. Morimoto K, Kaneko T, Iijima K, Koizumi A. Proliferative kinetics and chromosome damage in trisomy 21 lymphocyte cultures exposed to γ-rays and bleomycin. Cancer Res 1984;44:1499-1504.
30. Purrott RJ, Vulpis N, Lloyd DC. The use of harlequin staining to measure delay in the human lymphocyte cell cycle induced by in vitro X-irradiation. Mutat Res 1980;69:275-82.
31. 0 exposure to mitomycin C in vitro vs. in vivo. Mutat Res 1979;67:259-69.
32. 2-delay: potential application as radioprotectors. Physica Medica 2001;XVII(Suppl 1):205-9.
33. Vijayalaxmi, Reiter RJ, Herman TS, Meltz ML. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat Res 1998;397:203-8.
34. Vijayalaxmi, Reiter RJ, Sewerynek E, Poeggeler B, Leal BZ, Meltz ML. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiat Res 1995;143:102-6.
35. Vijayalaxmi, Reiter RJ, Leal BZ, Meltz ML. Effect of melatonin on mitotic and proliferation indices, and sister chromatid exchange in human blood lymphocytes. Mutat Res 1996;351:187-91.
36. Awara WM, El-Gohary M, El-Nabi SH, Fadel WA. In vivo and in vitro evaluation of the mutagenic potential of carbamazepine: Does melatonin have antimutagenic activity? Toxicology 1998;125:45-52.
37. Littlefield LG, Hoffman GR. Modulation of the clastogenic activity of ionising radiation and bleomycin by the aminothiol WR-1065. Environ Mol Mutagen 1993;22:225-30.
38. Reiter JR, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000;7:444-58.
39. 2- and cyclophosphamide-induced DNA damage. Mutagenesis 1999;14(1):107-12.
40. Reiter JR, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, Manchester LC, Vijayalaxmi, Kilic E, Kilic Ü. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 2004;56:159-70.